How AI Is Transforming Cell Line Development for Protein Production
Can early-stage data really predict high-producing clones? Learn how AI and mechanistic modeling are reshaping cell line development to support more reliable protein production.
The successful production of protein-based therapeutics depends on the availability of robust cell lines engineered to produce high yields of the target biomolecule efficiently and at scale. Traditionally, optimizing protein expression has involved conducting large numbers of trial-and-error experiments, intuition-driven choices, and resource- and time-intensive laboratory work.
Today, the predictive capabilities of artificial intelligence (AI) and machine learning (ML) algorithms are rapidly changing the way cell lines and bioprocesses are developed and optimized.
How AI Can Transform Cell Line Development
Each stage of cell line and bioprocess development generates a wealth of data, from cell morphology and viability to media composition and metabolite levels.
When AI tools and machine learning algorithms are implemented correctly at the right stages, they can effectively analyze complex, multivariate data to uncover patterns and predict which clones will reliably produce the target protein at high titers with the desired critical quality attributes (CQAs). This strategic application of technology reduces risk and shortens cell line development timelines.
AI-Powered Clone Screening
During cell line development, thousands of clones are screened to find the few that produce proteins at high titers. Sartorius CHO Cell Line Development Services uses data from single-cell cloning supported by the high-throughput automation capabilities of the Sartorius CellCelector™ to facilitate this level of screening in an efficient manner (Figure 1).
This approach generates a significant amount of imaging and fluorescence data that provide insights into the potential performance of a clonal population. AI and ML help scientists leverage this data by:
- Effectively differentiating and selecting high-producing clones to progress to clone expansion and evaluation.
- Applying supervised learning algorithms (e.g., neural networks, decision trees) to learn from early-stage clone data.
- Ranking clones for further investigation with high predictive accuracy.
Figure 1 - The integration of AI | ML in CHO cell line development workflows
The Value of AI in Cell Line Development
With these early AI-driven predictions, scientists can classify clones as high producers or low producers based on early-stage data (e.g., within four days of single-cell cloning). This supports the prompt identification and elimination of poor-performing clones, and the adjustment of parameters in real time, saving time and resources.
Combined with semi-automated pipelines and preprocessing strategies, AI enables fast, accurate clone ranking and performance validation.
In fact, a recent study by scientists at our Cell Line Development Center of Excellence in Ulm, Germany, showed up to 60% higher titer in selected clones using AI-driven models compared to traditional methods (Figure 1).1
Process Intensification: Adding Mechanistic Approaches to an AI-Driven Clone Selection Algorithm
Bioprocess scientists are increasingly turning to process intensification to boost productivity, economic efficiency, and sustainability.
To enable this shift, mechanistic approaches are being integrated with our AI | ML–driven clone selection algorithms, allowing the identification of clones optimized for both standard fed-batch and perfusion processes.
Hybrid modeling techniques using Ambr® 15 fed-batch data and perfusion simulations accelerate clone screening, reducing the time required to identify the optimal perfusion clone to 1–2 days and eliminating weeks of manual work. By significantly reducing perfusion clone selection time, we can focus on testing only the top clones, thereby eliminating unnecessary experimental and labor costs associated with excessive clone screening.
Automating process optimization using clone-specific parameters like cell-specific perfusion rate and bleed viable cell density helps ensure optimal conditions for growth and productivity.
This modeling approach ensures that clones selected early undergo an additional evaluation step before being chosen for perfusion.
Molecule-Agnostic Learning
Another valuable feature of AI is that models can learn across different molecules and modalities, especially when data is standardized. This makes the system:
- Flexible across monoclonal antibodies, bi- and multispecifics, and Fc-fusions.
- Capable of transfer learning, where insights from one project can accelerate another.
- Ideal for building generalizable platforms that work across diverse product pipelines.
Making Advanced Analytics Accessible
With the support of our data management system, we can seamlessly connect data from diverse sources, simplifying analysis and modeling applications. Modern platforms such as SIMCA® and Sartorius Cell Insights™ integrate complex machine learning and mechanistic approaches, making them accessible to scientists without the need for highly specialized computational expertise.
Higher Protein Titers, Faster
By integrating AI and ML into the cell line development workflow, we can help biopharma companies achieve:
- Faster time-to-clone, with automated single-cell cloning, and predictive modeling
- Higher titers and specific productivity in both fed-batch and perfusion settings
- Robust, molecule-agnostic selection
- Lower development costs and reduced risk of failure
Importantly, these tools are designed to complement—not replace—scientific expertise, supporting more confident and efficient decision-making.
Curious About Where to Start?
Learn how to turn your data into better outcomes. Discover more in our recent webinar, or talk to a cell line development expert today.
References
1. Safari, A., Schmidsberger, T., Stefura, F., Klein, J., Lindner, C., Van der Kamp, I., Müller, D., & Thiele, K. (n.d.) From single cell cloning to perfusion: Combined AI-driven and mechanistic clone selection model for cost-effective and time-efficient cell culture and bioprocessing [Poster]. Sartorius.